Comparative Pharmacology
Head-to-head clinical analysis: POSFREA versus TERAZOL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POSFREA versus TERAZOL 3.
POSFREA vs TERAZOL 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Terconazole is an azole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death.
IV 4 mg/kg once daily; infused over 90 minutes.
One applicatorful (approximately 5 g of 0.8% terconazole vaginal cream) intravaginally once daily at bedtime for 3 consecutive days.
None Documented
None Documented
12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
The terminal elimination half-life after intravaginal application is approximately 4-6 hours, reflecting local retention and slow systemic absorption of the small absorbed fraction.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Following intravaginal administration, terconazole is minimally absorbed (<5%) into systemic circulation. Absorbed drug is primarily metabolized in the liver and excreted via feces (approximately 50-60% as metabolites) and urine (approximately 20-30% as metabolites). Unabsorbed drug is excreted in feces.
Category C
Category C
Azole Antifungal
Azole Antifungal